Publication:
A Comparative Effectiveness Analysis Applying a 3-Way Propensity Score Matching to Real-World Data from the MSBase Registry in Preparation for a Cost-Effectiveness Model: Patients Switching Within First-Line Agents or to Either Natalizumab or Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Research Projects

Organizational Units

Journal Issue

Abstract

Description

70th Annual Meeting of the American-Academy-of-Neurology (AAN) -- APR 21-27, 2018 -- Los Angeles, CA

Keywords

Citation

WoS Q

Scopus Q

Source

Volume

90

Issue

Start Page

End Page

Endorsement

Review

Supplemented By

Referenced By